Lahuerta, Juan José <br/><br/>
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.  [electronic resource] 

 -  Haematologica  Nov 2010 
 - 1913-20 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2010.028027  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Busulfan--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Melphalan--administration & dosage<br/>Multiple Myeloma--mortality<br/>Myeloablative Agonists--administration & dosage<br/>Retrospective Studies<br/>Stem Cell Transplantation<br/>Transplantation Conditioning<br/>Transplantation, Autologous